AL Amyloidosis

AL Amyloidosis
J&J withMe in your country

AL amyloidosis and you

AL amyloidosis is one of the most common types of amyloidosis, where mutated white plasma cells in your bone marrow produce misfolded proteins creating deposits that affect organs such as the heart, kidneys, nerves, or parts of the digestive system. AL amyloidosis is not cancerous, although it may occasionally be associated with a rare type of blood cancer that also starts in white plasma cells called multiple myeloma.

Key topics

About AL Amyloidosis

Though AL amyloidosis is the most common form of amyloidosis, there are several types of the condition.

Symptoms

Symptoms for AL amyloidosis may be present before diagnosis. They range from fatigue and weakness to more serious problems that can impact organs such as the heart and kidneys.

Treatments

While there is no cure for AL amyloidosis, there are treatment options to help manage the condition.

Living with AL Amyloidosis

Get some tips on how to manage your day-to-day life with AL amyloidosis. Take care of your physical and emotional wellbeing.

Your Healthcare Team
You will meet many people during your care pathway. Understand the role each person will play in your treatment. This will vary from country to country.
Support and Caregivers

Although AL amyloidosis is rare, remember you are not alone. Gain access to support groups that can provide valuable insights into understanding a diagnosis.

References

Global Patient and Carer Experience Survey. (2021). Available at: https://www.clladvocates.net/wp-content/uploads/2023/09/Global-Leukemia-Experience-Survey_Full-Report.pdf. Last accessed: November 2024.
Alu, Aqu et al. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. Journal of Hematology & Oncology. 2022 Oct;15:138.
Tam CS, et al. Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial. Curr Med Res Opin. 2023 Sep:1-7.
Eichhorst B, et al. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35(9):762-768.
DrugBank Online. Warfarin. Available at: https://go.drugbank.com/drugs/DB00682. Last accessed: November 2024.
Lipsky A, et al. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2020 Dec;2020(1):336-345.
Cancer Research UK. Ibrutinib (Imbruvica). Available at: https://www.cancerresearchuk.org/about-cancer/treatment/drugs/ibrutinib. Last accessed: November 2024.
Macmillan Cancer Support. Ibrutinib (Imbruvica). Available at: https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/ibrutinib. Last accessed: November 2024.
Quartermaine C, et al. (2023). Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology, 5(5), pp.570–590.
Zeynep Tuğba Güven. CLL-256 Monocytosis Developing in the Course of Chronic Lymphocytic Leukemia: Case Report. 2024;24;Sup 1: S349-S350.
Valla K, et al. Atrial Fibrillation: Considerations for the Use of BTK Inhibitors. Cancer Network Oncology. 2018 Nov; 32(11):574-575.
Logo Janssen | Pharmaceutical Companies of Johnson & Johnson